Ani Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 05, 2020 at 07:01 am EST
Share
ANI Pharmaceuticals, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was USD 52.979 million compared to USD 51.337 million a year ago. Operating income was USD 2.802 million compared to USD 7.328 million a year ago. Net income was USD 434,000 compared to USD 3.895 million a year ago. Basic earnings per share from continuing operations was USD 0.04 compared to USD 0.32 a year ago. For the nine months, sales was USD 151.223 million compared to USD 158.581 million a year ago. Operating loss was USD 16.347 million compared to operating Income of USD 21.022 million a year ago. Net loss was USD 18.913 million compared to net income of USD 10.929 million a year ago. Basic loss per share from continuing operations was USD 1.58 compared to basic earnings per share from continuing operations of USD 0.91 a year ago. Diluted loss per share from continuing operations was USD 1.58 compared to diluted earnings per share from continuing operations of USD 0.89 a year ago.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
ANI PHARMACEUTICALS, INC. 
